Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12530/36400
Title: Raltegravir plus abacavir/lamivudine in virologically suppressed HIV-1-infected patients: 48-week results of the KIRAL study.
Authors: 
Mesh: 
Issue Date: 2018
Citation: PLoS ONE.2018;(13)6:e0198768
Abstract: Long-term combination antiretroviral therapy often results in toxicity/tolerability problems, which are one of the main reasons for switching treatment. Despite the favorable profile of raltegravir (RAL), data on its combination with abacavir/lamivudine (ABC/3TC) are scarce. Based on clinical data, we evaluated this regimen as a switching strategy.
PMID: 29902204
URI: https://hdl.handle.net/20.500.12530/36400
Rights: openAccess
Appears in Collections:Hospitales > H. U. Infanta Leonor > Artículos
Hospitales > H. U. Severo Ochoa > Artículos
Fundaciones e Institutos de Investigación > IIS H. U. La Princesa > Artículos
Fundaciones e Institutos de Investigación > IIS H. U. La Paz > Artículos
Fundaciones e Institutos de Investigación > IIS H. U. Ramón y Cajal > Artículos
Fundaciones e Institutos de Investigación > FIB H. U. Príncipe de Asturias > Artículos

Files in This Item:
File Description SizeFormat 
PMC6002106.pdf1.92 MBAdobe PDFThumbnail
View/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.